路易体痴呆症的经典脑脊液生物标志物。
Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies.
机构信息
2nd Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, "Attikon" General University Hospital, 12462 Athens, Greece.
出版信息
Medicina (Kaunas). 2022 Apr 28;58(5):612. doi: 10.3390/medicina58050612.
Abstract
The use and interpretation of diagnostic cerebrospinal fluid (CSF) biomarkers for neurodegenerative disorders, such as Dementia with Lewy bodies (DLB), represent a clinical challenge. According to the literature, the composition of CSF in DLB patients varies. Some patients present with reduced levels of amyloid, others with full Alzheimer Disease CSF profile (both reduced amyloid and increased phospho-tau) and some with a normal profile. Some patients may present with abnormal levels of a-synuclein. Continuous efforts will be required to establish useful CSF biomarkers for the early diagnosis of DLB. Given the heterogeneity of methods and results between studies, further validation is fundamental before conclusions can be drawn.
摘要
用于神经退行性疾病（如路易体痴呆症，DLB）的诊断性脑脊液（CSF）生物标志物的使用和解释是一个临床挑战。根据文献，DLB 患者的 CSF 组成不同。一些患者的淀粉样蛋白水平降低，另一些患者则具有完整的阿尔茨海默病 CSF 特征（淀粉样蛋白和磷酸化 tau 均降低），还有一些患者的 CSF 特征正常。一些患者可能表现出异常水平的 a-突触核蛋白。为了建立用于 DLB 早期诊断的有用 CSF 生物标志物，需要不断努力。鉴于研究之间方法和结果的异质性，在得出结论之前，进一步验证是至关重要的。
相似文献
1
Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies.路易体痴呆症的经典脑脊液生物标志物。
Medicina (Kaunas). 2022 Apr 28;58(5):612. doi: 10.3390/medicina58050612.
2
Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.脑脊液生物标志物（磷酸化tau181、总tau、Aβ42 和 Aβ40）在阿尔茨海默病和路易体痴呆前驱期的诊断价值。
J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.
3
Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.脑脊液阿尔茨海默病生物标志物有助于在疾病前驱期鉴别路易体痴呆与阿尔茨海默病。
J Neurol Neurosurg Psychiatry. 2018 May;89(5):467-475. doi: 10.1136/jnnp-2017-316385. Epub 2018 Jan 10.
4
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.帕金森病患者脑脊液中α-突触核蛋白和tau 浓度：一项队列研究。
Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X.
5
α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.α-突触核蛋白作为路易体痴呆症潜在的脑脊液生物标志物。
Mov Disord. 2018 Nov;33(11):1724-1733. doi: 10.1002/mds.111. Epub 2018 Nov 15.
6
CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.阿尔茨海默病和路易体痴呆症中神经元损伤生物标志物视蛋白样蛋白-1 的 CSF 水平。
J Neurochem. 2013 Dec;127(5):681-90. doi: 10.1111/jnc.12331. Epub 2013 Jun 26.
7
The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology.脑脊液 α-突触核蛋白和 tau/α-突触核蛋白比值对具有路易体病理的神经退行性疾病的诊断价值。
Eur J Neurol. 2020 Jan;27(1):43-50. doi: 10.1111/ene.14032. Epub 2019 Jul 24.
8
Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.脑脊液脂肪酸结合蛋白 3、α-突触核蛋白与阿尔茨海默病核心生物标志物在路易体疾病和阿尔茨海默病痴呆中的差异作用。
Alzheimers Res Ther. 2017 Jul 28;9(1):52. doi: 10.1186/s13195-017-0276-4.
9
Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.帕金森病、路易体痴呆或其他神经退行性疾病患者的脑脊液中α-突触核蛋白、淀粉样β、tau、磷酸化 tau 和神经元特异性烯醇化酶水平：与认知和核医学成像结果的关系。
Neurosci Lett. 2020 Jan 10;715:134564. doi: 10.1016/j.neulet.2019.134564. Epub 2019 Nov 13.
10
Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical Practice.脑脊液α-突触核蛋白有助于提高临床实践中路易体痴呆和阿尔茨海默病的鉴别诊断能力。
Int J Mol Sci. 2022 Nov 4;23(21):13488. doi: 10.3390/ijms232113488.
引用本文的文献
1
Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein.路易体痴呆：探索淀粉样β蛋白、tau蛋白和α-突触核蛋白的生物标志物及致病相互作用
Mol Neurodegener. 2025 Aug 12;20(1):90. doi: 10.1186/s13024-025-00879-0.
2
Dementia with Lewy bodies and Parkinson disease dementia - the same or different and is it important?路易体痴呆和帕金森病痴呆——相同还是不同，这重要吗？
Nat Rev Neurol. 2025 May 12. doi: 10.1038/s41582-025-01090-x.
3
Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure AT (AT) Alzheimer's Disease.混合性与纯萎缩性（AT）阿尔茨海默病中脑脊液经典生物标志物水平
Biomedicines. 2024 Dec 20;12(12):2904. doi: 10.3390/biomedicines12122904.
4
Biomarker Assessment in Parkinson's Disease Dementia and Dementia with Lewy Bodies by the Immunomagnetic Reduction Assay and Clinical Measures.通过免疫磁珠减少法和临床指标评估帕金森病痴呆和路易体痴呆中的生物标志物
J Alzheimers Dis Rep. 2024 Oct 25;8(1):1361-1371. doi: 10.3233/ADR-240110. eCollection 2024.
5
Cognitive trajectories preluding the onset of different dementia entities: a descriptive longitudinal study using the NACC database.认知轨迹先于不同痴呆实体的发病：使用 NACC 数据库的描述性纵向研究。
Aging Clin Exp Res. 2024 May 23;36(1):119. doi: 10.1007/s40520-024-02769-9.
6
Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice.神经退行性疾病的分子生物标志物：临床实践中其合理应用与解读实用指南
Int J Mol Sci. 2024 Apr 13;25(8):4323. doi: 10.3390/ijms25084323.
7
Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development.阿尔茨海默病和其他类型痴呆症的生物标志物：下一步走向病理生理学以支持临床实践和药物研发。
Medicina (Kaunas). 2022 Sep 30;58(10):1374. doi: 10.3390/medicina58101374.
本文引用的文献
1
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.路易体痴呆的体液和组织生物标志物：LBDA研讨会报告。
Front Neurol. 2022 Jan 31;12:805135. doi: 10.3389/fneur.2021.805135. eCollection 2021.
2
The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.帕金森病相关障碍中的神经炎症急性期反应。
Mov Disord. 2022 May;37(5):993-1003. doi: 10.1002/mds.28958. Epub 2022 Feb 8.
3
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers.α-突触核蛋白和β-突触核蛋白：从病理生理学到作为生物标志物的临床应用
Mov Disord. 2022 Apr;37(4):669-683. doi: 10.1002/mds.28941. Epub 2022 Feb 5.
4
Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies.脑脊液 α-突触核蛋白实时液滴震荡转换分析在路易体痴呆前驱期轻度认知障碍中的诊断价值。
Neurology. 2021 Aug 31;97(9):e930-e940. doi: 10.1212/WNL.0000000000012438. Epub 2021 Jul 1.
5
Cerebrospinal Fluid -Synuclein Species in Cognitive and Movements Disorders.认知和运动障碍中的脑脊液α-突触核蛋白亚型
Brain Sci. 2021 Jan 17;11(1):119. doi: 10.3390/brainsci11010119.
6
Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease.血浆磷酸化tau 蛋白可识别路易体病患者的阿尔茨海默病共病病理。
Mov Disord. 2021 Mar;36(3):767-771. doi: 10.1002/mds.28370. Epub 2020 Dec 7.
7
Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.用于鉴别额颞叶痴呆和路易体痴呆与阿尔茨海默病的新型体液生物标志物：一项系统评价
J Neurol Sci. 2020 Aug 15;415:116886. doi: 10.1016/j.jns.2020.116886. Epub 2020 May 11.
8
Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.路易体是否含有α-突触核蛋白纤维？这有关系吗？对近期报告的简要历史回顾和批判性分析。
Neurobiol Dis. 2020 Jul;141:104876. doi: 10.1016/j.nbd.2020.104876. Epub 2020 Apr 25.
9
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.路易体痴呆患者脑脊液中的淀粉样β肽。
Alzheimers Res Ther. 2019 Oct 10;11(1):83. doi: 10.1186/s13195-019-0537-5.
10
In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies.路易体痴呆症中阿尔茨海默病生物标志物的体内流行率。
Dement Geriatr Cogn Disord. 2019;47(4-6):289-296. doi: 10.1159/000500567. Epub 2019 Jul 16.
Zotero 插件